Medical cannabis has been legal in Canada since 2001—nearly twenty years before recreational cannabis was legalized in 2018. Yet it remains one of the least well-understood treatments among patients who could benefit from it, and one of the topics on which clinicians themselves are most reluctant to take a clear stance.
This guide answers the concrete questions posed by patients considering medical cannabis in Quebec in 2026: how it differs from recreational cannabis, for which conditions the clinical data is strongest, how the prescription process works at Clinique Omicron, what insurance covers treatment and under what conditions, and what real risks to be aware of before starting.
The legalization of recreational cannabis in October 2018 has created ongoing confusion among many patients: if cannabis is legally available over the counter, why go through a doctor? The answer lies in real and concrete differences on the legal, medical, and financial fronts.
The Regulatory Framework
Medical cannabis in Canada is governed by Health Canada’s Medical Cannabis Access Regulations (MCAR)—a regulatory framework distinct from the one governing recreational cannabis sold in stores operated by the Société québécoise du cannabis (SQDC). This regulatory framework imposes strict requirements on licensed producers: documented quality controls, certified THC and CBD levels per batch, tested and certified absence of contaminants, and full product traceability.
Medically obtained cannabis is produced by growers authorized by Health Canada and delivered directly to the patient by mail—without going through the SQDC. Patients are not limited to the formats and concentrations available in the recreational retail market—they can access formulations, concentrations, and routes of administration tailored to their specific clinical profile.
Legal possession of medical cannabis is not subject to the limits that apply to recreational cannabis—a registered patient with a valid medical certificate may possess the amount prescribed by their doctor, which may exceed the recreational possession limit of 30 grams.
Quality and traceability
Medical cannabis purchased from a Health Canada-authorized producer is subject to pharmaceutical-grade quality standards—each batch is tested for cannabinoid content, pesticides, heavy metals, mold, and bacteria. Patients receive a certificate of analysis for each batch and can verify exactly what they are consuming.
Recreational cannabis sold at SQDC is also subject to regulatory quality controls, but the medical setting offers more rigorous traceability and documentation - particularly relevant for patients who use cannabis in a documented therapeutic context and for whom consistency of concentrations between batches is clinically important.
Dosage and Medical Supervision
Medically obtained cannabis is prescribed within the context of a therapeutic relationship with a physician—which involves a preliminary assessment of the medical indication, a discussion of the appropriate route of administration and dosage form, a dosage initiated cautiously with gradual adjustments, and documented medical follow-up. This clinical framework reduces the risk of inappropriate dosing, undetected drug interactions, and the exacerbation of contraindicated psychiatric conditions.
Reimbursement — the Decisive Advantage
This is often the most decisive factor in a patient’s choice between medical and recreational cannabis: medical cannabis may be reimbursed by certain private insurance plans and certain compensation programs—Veterans Affairs Canada, CNESST, SAAQ—under certain conditions. Recreational cannabis, purchased from the SQDC, is never reimbursable. This distinction is discussed in detail in the section on reimbursement.
Conditions that can be treated with medical cannabis
Medical cannabis is not a cure-all, and the clinical evidence is not equally robust for all the conditions cited. Here is an honest overview of the current state of the evidence for the most common indications.
Chronic pain
Chronic pain—particularly neuropathic pain—is the condition for which the body of clinical evidence on medical cannabis is the strongest and most consistent. Meta-analyses published in leading journals document a modest but statistically significant analgesic effect for peripheral and central neuropathic pain, pain associated with multiple sclerosis, and chronic non-cancer pain refractory to conventional treatments.
Cannabis generally does not eliminate pain completely—it reduces it enough to improve daily functioning, sleep, and quality of life. This is a realistic therapeutic goal, distinct from a cure, and clinically relevant for patients whose pain persists despite multiple lines of conventional treatment.
The most well-documented indication remains neuropathic pain—pain associated with damage to or dysfunction of the nervous system, such as diabetic neuropathy, postherpetic neuralgia, phantom pain, and pain associated with neurological disorders. Chronic nociceptive pain responds more variably.
Insomnia associated with a medical condition
Insomnia is frequently cited as a reason by patients seeking medical cannabis—and clinical data, although less robust than for neuropathic pain, suggests efficacy in reducing sleep onset latency and nighttime awakenings, primarily through the effects of CBD and balanced CBD:THC ratios.
The important clinical distinction is that medical cannabis is more appropriate for insomnia associated with an underlying medical condition—such as chronic pain that prevents falling asleep, PTSD with nightmares and nocturnal hypervigilance, or nocturnal spasticity—than for primary insomnia on its own, for which cognitive-behavioral therapy for insomnia (CBT-I) remains the recommended first-line treatment.
Chronic use of THC for sleep also raises the question of its long-term impact on sleep architecture—THC reduces rapid eye movement (REM) sleep, which may have implications for memory consolidation and emotional processing. This point warrants discussion during a medical consultation.
PTSD - post-traumatic stress disorder
PTSD is a condition for which clinical interest in medical cannabis has increased significantly in recent years, driven in particular by data from the Canadian Armed Forces’ veteran programs and Veterans Affairs Canada — which cover medical cannabis for veterans with documented PTSD.
The symptoms for which the data are most encouraging include nightmares and sleep disturbances, hypervigilance and excessive responses to stimuli, and chronic anxiety associated with PTSD. Medical cannabis for this condition is generally used as a supplement—not a replacement—for evidence-based psychotherapies for PTSD, including cognitive therapy (CT) and eye movement desensitization and reprocessing (EMDR).
Chemotherapy-related nausea and vomiting
This is one of the best-documented historical indications for cannabinoids—medications containing synthetic THC (dronabinol, nabilone) have been approved by Health Canada since the 1980s for chemotherapy-induced nausea and vomiting that is refractory to conventional antiemetics. Nabilone (Cesamet) is available by prescription in Canada for this indication and is covered by the RAMQ under certain conditions.
Medical cannabis, whether in its plant form or as an oil, is a therapeutic option for patients who cannot tolerate standard antiemetics or who are seeking a complementary option to improve their quality of life during cancer treatment. It is recommended to consult with an oncologist at the same time to ensure there are no interactions with the chemotherapy regimen.
Spasticity - multiple sclerosis and spinal cord injury
Spasticity associated with multiple sclerosis (MS) and spinal cord injuries is a recognized indication by several medical associations and is well documented in the literature. Sativex—an oral spray with a 1:1 THC:CBD ratio—is approved by Health Canada specifically for moderate-to-severe spasticity associated with MS that is refractory to conventional treatments. The use of medical cannabis in other formulations for this indication follows the same therapeutic rationale.
Other conditions — more limited data
Several other conditions are frequently mentioned in connection with medical cannabis—drug-resistant epilepsy (the evidence for CBD is strong, particularly for certain pediatric syndromes, and Epidiolex—a pharmaceutical CBD—is approved for this indication), fibromyalgia, chronic inflammatory bowel diseases, and anxiety. For some of these conditions, the evidence is promising but still insufficient to support firm recommendations. Your doctor will assess whether your specific clinical presentation constitutes a medically justified indication.
Prescription process at Clinique Omicron
The term «prescription» for medical cannabis is actually a misuse of legal language - strictly speaking, the doctor issues a "prescription" for the drug. medical document allowing the patient to register with a Health Canada-authorized producer, rather than obtaining a traditional prescription. The actual process involves several distinct steps.
Initial medical consultation
The first step is a comprehensive medical consultation at Clinique Omicron, either in person in Brossard or Saint-Hubert, or via telemedicine for patients eligible for a remote evaluation.
As with all appointments at Clinique Omicron, a nurse conducts a triage before the medical consultation—collecting a complete medical history, a list of current medications, the nature and duration of symptoms, treatments already tried for the presented condition, and their results. This structured clinical triage allows the doctor to arrive at the consultation with a clear picture of the patient’s condition and to make the best use of the time available for evaluation and discussion.
During the consultation, the doctor will assess whether your condition constitutes a medically justified indication for medical cannabis—based on available clinical data and the guidelines of the Canadian Medical Association. The doctor documents the conventional treatments you have already tried and their outcomes—medical cannabis is generally indicated for conditions that are refractory to first-line treatments rather than as a first-line treatment. The doctor assesses any contraindications and risk factors specific to your situation. They discuss realistic expectations, available forms, routes of administration, and the titration approach.
Health Canada form and medical document
If the doctor concludes that medical cannabis is medically justified for your situation, he completes the medical document in accordance with Health Canada regulatory requirements. This document indicates your identity, the authorized daily quantity in grams of dried cannabis equivalent, and the period of validity of the document - generally one year, renewable.
The daily amount listed is a medical decision based on your condition, your risk profile, and the estimated therapeutic dosage—it is not permission to consume that amount daily, but a regulatory limit that defines the amount you may legally possess.
Registration with an authorized producer
With the medical document in hand, you register directly with the Health Canada-authorized producer of your choice - an administrative process you do yourself, usually online at the producer's website. Major authorized producers in Canada include Tilray, Aurora, MedReleaf, Aphria, and many others. Each producer offers a different catalog of products - dried flowers in different varieties, oils, capsules, extracts - with varying THC and CBD concentrations.
Your Clinique Omicron doctor can direct you to the producers whose catalog corresponds to your therapeutic profile, and advise you on the formats and concentrations best suited to your condition and personal situation. The cannabis is then delivered directly to your address by secure mail.
Medical follow-up
Medical cannabis is not a treatment that is started and then left unsupervised. Regular medical follow-up—typically one month after treatment begins, then at three and six months—allows for an assessment of the treatment’s effectiveness on target symptoms, dose adjustments as needed, the detection of side effects, and periodic reassessment of the medical indication. The medical authorization must be renewed—usually annually—which requires regular medical reevaluation.
Insurance reimbursement
Reimbursement for medical cannabis through employer-sponsored group insurance plans has increased significantly in Canada since 2018—a growing number of plans now cover medical cannabis under certain conditions, although coverage is still far from universal.
Plans that cover medical cannabis generally require several cumulative conditions: a valid medical document signed by a licensed physician documenting the therapeutic indication, registration with a Health Canada-authorized producer, a documented medical diagnosis that falls within the conditions covered by the plan, and, in some cases, proof that conventional treatments have been tried and have proven ineffective.
Insurance companies that offer reimbursement programs for medical cannabis in Canada include Sun Life, Manulife, Great-West Life (Canada Life), Desjardins, and several others—each plan has its own criteria and limits. Reimbursement amounts range from 1,500 $ to 6,000 $ per year depending on the plan, with limits per gram or per day.
Practical steps: Contact your insurance provider or your employer’s human resources department to verify whether your plan includes coverage for medical cannabis and what documents are required to file a claim. Clinique Omicron provides a medical letter and the necessary clinical documentation to support your insurance claim.
Veterans Affairs Canada
The Veterans Affairs Canada (VAC) program covers medical cannabis for eligible veterans, with reimbursement of up to 3 grams per day for covered conditions—including PTSD, chronic pain, and several other service-related conditions. Documentation requirements include a medical certificate from a licensed physician and registration with a licensed producer. If you are a veteran, this coverage is significant and worth exploring with your doctor.
CNESST and SAAQ
The Commission on Occupational Standards, Equity, Health, and Safety (CNESST) and the Quebec Automobile Insurance Corporation (SAAQ) cover medical cannabis in specific circumstances related to work-related injuries or traffic accidents, respectively—when treatment is medically justified for the aftereffects of these events. Coverage is granted on a case-by-case basis based on medical records.
RAMQ
The RAMQ does not cover medical cannabis as such—plant-based or oil-based medical cannabis products are not listed on the formulary of reimbursed medications. Nabilone (Cesamet), a prescription synthetic THC, is covered by the RAMQ under specific criteria for refractory chemotherapy-induced nausea and vomiting—but it is a pharmaceutical drug distinct from medical cannabis as defined by Health Canada’s program.
Side effects and medical precautions
Balanced information on medical cannabis includes an honest presentation of the risks - not to discourage patients who have a medically justified indication, but so that the therapeutic decision is informed.
Acute side effects of THC
THC—tetrahydrocannabinol—is the psychoactive cannabinoid responsible for the «high.» In a medical setting, therapeutic doses are generally much lower than recreational doses, and the goal is to achieve an analgesic or anxiolytic effect without significant intoxication—but THC-related side effects can occur, particularly at the start of treatment or during dose adjustments.
The most common side effects include sedation and drowsiness—which are important for patients who need to drive or operate machinery, and which require strict adherence to the rule: do not drive for several hours after consuming cannabis containing THC. Dizziness, tachycardia, and orthostatic hypotension may occur, particularly in older adults and patients with cardiovascular conditions. Dry mouth and increased appetite are common. Difficulty concentrating and short-term cognitive impairments are expected with high doses of THC.
Paradoxical anxiety and panic attacks can be triggered by THC, particularly at high doses or in patients with a history of anxiety disorders — this is one of the reasons why gradual titration starting with low doses is a fundamental principle of medical cannabis prescribing.
Long-term effects
Regular and prolonged use of cannabis with a high THC content is associated with documented risks that must be taken into account in treatment decisions.
Visit dependency — cannabis use disorder with formal diagnostic criteria — develops in approximately 9 % of regular users, with a higher prevalence among those who begin using during adolescence and among those with a history of dependence on other substances. Dependence on medical cannabis is a clinical reality that warrants attention, not a taboo to be swept under the rug.
Long-term effects on cognition—working memory, processing speed, and executive functions—have been documented with chronic use of high-THC cannabis, with partial recovery upon cessation. The impact is more pronounced in people who begin using cannabis before brain development is complete, that is, before about age 25.
The association between cannabis use and an increased risk of psychosis and schizophrenia is well documented in the epidemiological literature—the risk is proportional to THC content, frequency of use, and individual genetic vulnerability. This association is the primary reason why a personal or family history of psychosis constitutes a formal contraindication to medical cannabis containing THC.
Drug interactions
Cannabinoids are metabolized by the CYP450 enzyme system—primarily CYP3A4 and CYP2C9—which creates the potential for pharmacokinetic interactions with many commonly prescribed medications.
Visit anticoagulants, particularly warfarin, have a documented clinically significant interaction—cannabis can increase the anticoagulant effect and requires closer monitoring of the INR at the start of treatment. The immunosuppressants such as tacrolimus and cyclosporine, can have their concentrations altered by cannabis - an interaction particularly relevant to transplant patients. The antidepressants and anxiolytics may have additive pharmacodynamic interactions with cannabis. The benzodiazepines and opioids used in combination with cannabis can produce additive respiratory depression in high doses.
A complete list of your current medications must be provided to your doctor during the medical cannabis consultation - this medication review is a non-negotiable clinical step.
Contraindications
Certain contraindications are absolute - medical cannabis containing THC is formally contraindicated in the following situations: personal history of psychosis, schizophrenia or bipolar disorder with psychotic episodes, pregnancy and breastfeeding, history of severe allergic reaction to cannabis, under 25 years of age except for very specific indications under specialized supervision.
Other contraindications are relative and require a case-by-case evaluation: a history of dependence on other substances, significant cardiovascular conditions including heart failure and arrhythmia, severe respiratory conditions for inhaled forms, and a history of severe major depressive episodes.
Safe dosing - the fundamental principle
Le principe de titration progressive — « commencer bas, aller lentement » — est le fondement de toute prescription médicale de cannabis. La dose efficace minimale est l’objectif thérapeutique, pas la dose maximale tolérée. Pour les patients naïfs au cannabis, les doses initiales sont très faibles — quelques milligrammes de THC — augmentées progressivement selon la tolérance et l’effet clinique, sur plusieurs semaines à plusieurs mois.
La voie d’administration influence directement la sécurité du traitement. Les huiles et capsules orales ont une absorption lente et un effet d’apparition progressif — le pic plasmatique est atteint en 1 à 3 heures, ce qui facilite la titration et réduit le risque de surdosage accidentel. L’inhalation — vaporisation plutôt que combustion en contexte médical — produit un effet d’apparition rapide en quelques minutes, ce qui permet un meilleur ajustement dose-effet en temps réel mais nécessite plus d’expérience pour éviter une consommation excessive.
Frequently asked questions
Les réponses aux questions les plus fréquentes sur ce sujet.
Techniquement, il ne s’agit pas d’une ordonnance au sens pharmaceutique classique, mais d’un medical documentdélivré par un médecin autorisé et conforme aux exigences de Santé Canada. Ce document vous autorise à vous inscrire auprès d’un producteur autorisé et à recevoir du cannabis médical par courrier. Sans ce document médical signé par un médecin, vous ne pouvez pas accéder au programme de cannabis médical de Santé Canada. La consultation médicale préalable est obligatoire — elle n’est pas une formalité administrative mais une évaluation clinique réelle.
In the vast majority of cases, medical cannabis is used to treat complementary et non en remplacement des médicaments déjà prescrits — particulièrement pour les conditions complexes comme la douleur chronique, le PTSD, ou la spasticité. Dans certains cas, une amélioration des symptômes avec le cannabis peut permettre de réduire les doses d’autres médicaments — notamment les opioïdes pour la douleur chronique — mais cette modification ne doit jamais se faire de façon autonome. Toute modification de votre traitement médicamenteux doit être discutée et supervisée par votre médecin.
Oui — aucun médecin n’est légalement obligé de délivrer un document médical pour le cannabis. Certains médecins de famille sont réticents à s’engager dans cette pratique par manque de formation ou par principe. Si votre médecin de famille ne prescrit pas de cannabis médical, vous pouvez consulter un médecin de Clinique Omicron qui évaluera votre dossier et déterminera si vous êtes un candidat approprié.
Non, si votre traitement contient du THC et que vous l’avez consommé récemment. La conduite avec facultés affaiblies par le THC est une infraction criminelle au Canada, identique à la conduite en état d’ivresse alcoolique. Le délai après lequel la conduite est sécuritaire dépend de la dose, de la voie d’administration, de votre tolérance individuelle, et du format consommé — il n’existe pas de règle universelle précise. En pratique médicale, il est recommandé d’éviter de conduire dans les heures suivant la consommation de cannabis contenant du THC, et d’avoir une discussion explicite avec votre médecin sur la conduite automobile dans le cadre de votre traitement.
Le CBD — cannabidiol — est le cannabinoïde non psychoactif du cannabis, dont le profil de sécurité est significativement plus favorable que celui du THC. Il ne produit pas d’effet psychoactif, n’est pas associé aux risques psychiatriques du THC, et ne cause pas de déficience de conduite. Les produits à base de CBD pur ou à ratio CBD élevé/THC minimal ont un profil de risque différent et sont souvent mieux tolérés. Les interactions médicamenteuses du CBD existent cependant — notamment avec les antiépileptiques et les anticoagulants — et la consultation médicale reste nécessaire même pour les formulations CBD-dominantes.
Specialized medicine - Specialist physicians | Clinique Omicron
Omicron Clinic
Need to consult a doctor?
In-person or via telemedicine, anywhere in Quebec.
We accept insurance. Telemedicine consultations available 7 days a week. No family doctor required.
